sodium diisopropylamide | 72316-19-9

• 分子结构分类: 有机化合物 - 有机盐 - 有机金属盐
• 英文名称: sodium diisopropylamide
• 英文别名: sodium diisopropylamine；NaDA；sodium;di(propan-2-yl)azanide
• CAS: 72316-19-9
• 化学式: C₆H₁₄N*Na
• 分子量: 123.174
• InChiKey: YHOBGCSGTGDMLF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.82
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  bis(1-methyl-1H-imidazol-3-yl)dihydroboronium iodide 、 sodium diisopropylamide 以 乙醚 为溶剂， 反应 3.0h， 以54%的产率得到
  参考文献：
  名称：

  Influence of Pyrazolate vs N-Heterocyclic Carbene Ligands on the Slow Magnetic Relaxation of Homoleptic Trischelate Lanthanide(III) and Uranium(III) Complexes

  摘要：

  Two isostructural series of trigonal prismatic complexes, M(Bp(Me))(3) and M(Bc(Me))(3) (M = Y, Tb, Dy, Ho, Er, U; [Be-Me](-) = dihydrobis(methypyrazolyl)borate; [Bc(Me)](-) = dihydrobis(methylimidazolyl)borate) are synthesized and fully characterized to examine the influence of ligand donor strength on slow magnetic relaxation. Investigation of the dynamic magnetic properties reveals that the oblate electron density distributions of the Tb3+, Dy3+, and U3+ metal ions within the axial ligand field lead to slow relaxation upon application of a small dc magnetic field. Significantly, the magnetization relaxation is orders of magnitude slower for the N-heterocyclic carbene complexes, M(Bc(Me))(3), than for the isomeric pyrazolate complexes, M(Bp(Me))(3). Further, investigation of magnetically dilute samples containing 11-14 mol % of Tb3+, Dy3+, or U3+ within the corresponding Y3+ complex matrix reveals thermally activated relaxation is favored for the M(Bc(Me))(3) complexes, even when dipolar interactions are largely absent. Notably, the dilute species U(Bc(Me))(3) exhibits U-eff approximate to 33 cm(-1), representing the highest barrier yet observed for a U3+ molecule demonstrating slow relaxation. Additional analysis through lanthanide XANES, X-band EPR, and H-1 NMR spectroscopies provides evidence that the origin of the slower relaxation derives from the greater magnetic anisotropy enforced within the strongly donating N-heterocyclic carbene coordination sphere. These results show that, like molecular symmetry, ligand-donating ability is a variable that can be controlled to the advantage of the synthetic chemist in the design of single-molecule magnets with enhanced relaxation barriers.

  DOI：

  10.1021/ja501569t
• 作为产物：
  描述：

  二异丙胺 在 sodium 、 天然橡胶 作用下， 以 四氢呋喃 为溶剂， 反应 0.75h， 生成 sodium diisopropylamide
  参考文献：
  名称：

  伊波沙霉素的实用革兰氏规模合成，一种有效的候选抗生素

  摘要：

  介绍了伊波沙霉素的克级合成，伊波沙霉素是一种带有融合双环氨基酸残基的候选抗生素。该路线的关键转变涉及分子内氢化硅烷化-氧化序列以设置双环支架的环融合立体中心。该合成的其他显着特征包括假苯胺酰胺的高产率、高度非对映选择性烷基化、会聚 sp 3 -sp 2 Negishi 偶联和一锅转缩醛化还原反应以形成目标化合物的氧杂环丁烷环。这种合成策略的实施提供了大量的伊波沙霉素，以允许其在小鼠感染模型中进行体内分析。

  DOI：

  10.1021/jacs.1c03529
• 作为试剂：
  描述：

  calcium iodide 、 四氢呋喃 、 在 sodium diisopropylamide 作用下， 以38 %的产率得到
  参考文献：
  名称：

  II族金属的占用：第一种碱土金属负载的过渡金属碳酸盐配合物的合成和表征

  摘要：

  由碱土金属负载的碳酸镍络合物已经通过相应碱金属前体的盐复分解获得。新的配合物在溶液中发生类似 Schlenk 的交换反应，并已通过核磁共振波谱进行了研究。还研究了它们对环氧化物和一氧化碳的反应性。

  DOI：

  10.1039/d4cc01682c

文献信息

• Use of Rylene Derivatives as Photosensitizers in Solar Cells
  申请人：Pschirer Neil Gregory

  公开号：US20080269482A1

  公开（公告）日：2008-10-30

  Use of rylene derivatives I with the following definition of the variables: X together both —COOM; Y a radical -L-NR 1 R 2 (y1) -L-Z-R 3 (y2) the other radical hydrogen; together both hydrogen; R is optionally substituted (het)aryloxy, (het)arylthio; P is —NR 1 R 2 ; B is alkylene; optionally substituted phenylene; combinations thereof; A is —COOM; —SO 3 M; —PO 3 M 2 ; D is optionally substituted phenylene, naphthylene, pyridylene; M is hydrogen; alkali metal cation; [NR 5 ] 4 + ; L is a chemical bond; optionally indirectly bonded, optionally substituted (het)arylene radical; R 1 , R 2 are optionally substituted (cyclo)alkyl, (het)aryl; together optionally substituted ring comprising the nitrogen atom; Z is —O—; —S—; R 3 is optionally substituted alkyl, (het)aryl; R′ is hydrogen; optionally substituted (cyclo)alkyl, (het)aryl; R 5 is hydrogen; optionally substituted alkyl (het)aryl; m is 0, 1, 2; n, p m=0: 0, 2, 4 where: n+p=2, 4, if appropriate 0; m=1: 0, 2, 4 where: n+p=0, 2, 4; m=2: 0, 4, 6 where: n+p=0, 4, 6, or of mixtures thereof as photosensitizers in solar cells.

  使用以下变量定义的莱伦衍生物I的用途： X一起 两者都是-COOM; Y是一个基团 -L-NR 1 R 2 (y1) -L-Z-R 3 (y2) 另一个基团是氢; 一起 两者都是氢; R可选择地被取代为(het)芳氧基，(het)芳基硫基; P是-NR 1 R 2 ; B是烷基; 可选择地被取代的苯基; 它们的组合; A是-COOM; -SO 3 M; -PO 3 M 2 ; D可选择地被取代为苯基，萘基，吡啶基; M是氢; 碱金属阳离子; [NR 5 ] 4 + ; L是化学键; 可选择地间接键合，可选择地被取代的(het)芳基基团; R 1 ，R 2 可选择地被取代的(环)烷基，(het)芳基; 一起可选择地被取代的环，其中包括氮原子; Z是-O-; -S-; R 3 可选择地被取代的烷基，(het)芳基; R′是氢; 可选择地被取代的(环)烷基，(het)芳基; R 5 是氢; 可选择地被取代的烷基(het)芳基; m为0, 1, 2; n, p, m=0: 0, 2, 4其中：n+p=2, 4，如果适用为0; m=1: 0, 2, 4其中：n+p=0, 2, 4; m=2: 0, 4, 6其中：n+p=0, 4, 6， 或者作为太阳能电池中的光敏剂的混合物。
• [EN] PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIDINE EN TANT QUE BLOQUANTS DE TTX-S
  申请人：RAQUALIA PHARMA INC

  公开号：WO2014068988A1

  公开（公告）日：2014-05-08

  The present invention relates to pyrazolopyridine derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

  本发明涉及吡唑并吡啶衍生物，这些衍生物具有阻断TTX-S型电压门控钠通道的活性，并且在治疗或预防涉及电压门控钠通道的疾病和障碍中是有用的。该发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在预防或治疗涉及电压门控钠通道的疾病中的用途。
• METHOD FOR MANUFACTURING PHOSPHONOCROTONIC ACID DERIVATIVE
  申请人：Ina Shinji

  公开号：US20140051876A1

  公开（公告）日：2014-02-20

  Provided is a method of manufacturing a high quality phosphonocrotonic acid derivative. The present invention is a method of manufacturing a compound represented by the following Formula (3) by reacting a compound represented by the following Formula (1) with a compound represented by the following Formula (2), which comprises a treatment process using an acid or base. [in the formula, R 1 represents a C 1-6 linear or branched alkyl group that may be substituted by a C 6-10 aryl group, a C 2-6 linear or branched alkenyl group that may be substituted by a C 6-10 aryl group, a C 2-6 linear or branched alkynyl group that may be substituted by a C 6-10 aryl group, or a C 6-10 aryl group, R 2 represents a hydrogen atom, or a C 1-6 linear or branched alkyl group that may be substituted by a C 6-10 aryl group, R 3 represents a C 1-6 linear or branched alkyl group, a C 6-10 aryl group, or a halogen atom, and X represents a halogen atom, and multiple R 1 s may be the same or different].

  提供了一种制造高质量磷酰肟酸衍生物的方法。本发明是一种通过用表示以下公式（1）的化合物与表示以下公式（2）的化合物反应，制造表示以下公式（3）的化合物的方法，该方法包括使用酸或碱的处理过程。 [在公式中，R1表示可以由C6-10芳基取代的C1-6直链或支链烷基，可以由C6-10芳基取代的C2-6直链或支链烯基，可以由C6-10芳基取代的C2-6直链或支链炔基，或C6-10芳基；R2表示氢原子或可以由C6-10芳基取代的C1-6直链或支链烷基；R3表示C1-6直链或支链烷基，C6-10芳基或卤素原子；X表示卤素原子，多个R1可以是相同的或不同的]。
• Oxyindole derivatives
  申请人：Uchida Chikara

  公开号：US20060194842A1

  公开（公告）日：2006-08-31

  This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: A, R 1 , R 2 , R 3 , R 4 and R 5 are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT 4 agonistic activity such as, but not limited to, as gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageal disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes or apnea syndrome.

  这项发明涉及以下式（I）的化合物： 或其药学上可接受的盐，其中： A，R1，R2，R3，R4和R5分别如本文所述或药学上可接受的盐，以及含有这种化合物的组合物和利用这种化合物治疗由5-HT 4 激动活性介导的疾病的用途，例如但不限于胃食管反流病、胃肠疾病、胃动力障碍、非溃疡性消化不良、功能性消化不良、肠易激综合征（IBS）、便秘、消化不良、食管炎、胃食管疾病、恶心、中枢神经系统疾病、阿尔茨海默病、认知障碍、呕吐、偏头痛、神经系统疾病、疼痛、心血管疾病、心力衰竭、心律失常、糖尿病或呼吸暂停综合征。
• Method for producing transition metal compounds and their use for the polymerization of olefins
  申请人：——

  公开号：US20030191334A1

  公开（公告）日：2003-10-09

  The invention relates to a method for producing special transition metal compounds, to novel transition metal compounds and to their use for the polymerization of olefins.

  这项发明涉及一种生产特殊过渡金属化合物的方法，新型过渡金属化合物以及它们用于烯烃聚合的用途。